096760.KS
JW Holdings Corporation
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 4,180.00
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1010.8B | 969.0B | 887.7B | 928.1B | 864.5B |
| Cost of Revenue | 507.4B | 496.6B | 452.5B | 481.9B | 464.6B |
| Gross Profit | 503.9B | 472.9B | 435.2B | 446.2B | 400.0B |
| Operating Expenses | |||||
| R&D Expense | 47.7B | 48.9B | 39.1B | 33.7B | 33.1B |
| SG&A Expense | 181.5B | 149.8B | 146.1B | 150.6B | 240.6B |
| General & Admin Expense | 96.5B | 95.7B | 90.8B | 91.8B | 81.3B |
| Selling & Marketing Expense | 55.4B | 54.1B | 55.3B | 58.9B | 64.7B |
| Other Expenses | 110.5B | 110.6B | 103.5B | 116.9B | 116.4B |
| Total Operating Expenses | 322.9B | 309.3B | 288.7B | 301.3B | 273.8B |
| Cost and Expenses | 820.0B | 805.9B | 741.2B | 784.4B | 738.3B |
| Operating Income (EBIT) | 190.4B | 163.7B | 146.5B | 143.7B | 110.7B |
| Non-Operating | |||||
| Interest Income | 8.1B | 3.2B | 7.1B | 6.7B | 445.9M |
| Interest Expense | 19.4B | 19.9B | 32.2B | 32.5B | 25.3B |
| Net Interest Income | (11.2B) | (16.6B) | (25.0B) | (25.8B) | (24.8B) |
| Other Non-Op Income/Expense | (12.6B) | (19.4B) | 11.6B | (90.3B) | (39.7B) |
| Non-Operating Income (excl Interest) | 3.8B | — | (43.8B) | 59.4B | 8.0B |
| EBT (Pre-Tax Income) | 177.8B | 144.3B | 158.1B | 53.4B | 71.0B |
| Income Tax Expense | 21.1B | 28.8B | 35.4B | 22.4B | 24.5B |
| Bottom Line | |||||
| Net Income | 84.5B | 58.5B | 62.6B | 19.0B | 22.2B |
| Earnings from Cont. Ops | 156.7B | 115.5B | 122.8B | 31.0B | 46.5B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 84.5B | 58.5B | 62.6B | 19.0B | 22.2B |
| Per Share | |||||
| Basic EPS | ₩1,219 | ₩841 | ₩874 | ₩265 | ₩306 |
| Diluted EPS | ₩1,219 | ₩841 | ₩874 | ₩265 | ₩306 |
| Revenue Per Share | ₩14,609 | ₩13,904 | ₩12,394 | ₩13,219 | ₩11,964 |
| Shares | |||||
| Basic Shares Outstanding | 69.2M | 69.7M | 71.6M | 70.2M | 72.3M |
| Diluted Shares Outstanding | 69.2M | 69.7M | 71.6M | 70.3M | 72.3M |
| Profitability Metrics | |||||
| EBITDA | 149.6B | 207.3B | 231.4B | 128.5B | 142.8B |
| D&A | 44.8B | 43.6B | 41.1B | 44.2B | 40.1B |
| EBIT | 104.8B | 163.7B | 190.3B | 84.3B | 102.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026